Gender-specific responses of lean body composition and non-gender-specific cardiac function improvement after GH replacement in GH-deficient adults.

What Was Tested

The paper reports a study of Human Growth Hormone, published as a randomized controlled trial.

GH deficiency (GHD) in adulthood is accompanied by physical and psychological impairments.

Who Took Part

According to the abstract, 55 patients were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

One hundred fifteen patients (67 male, 48 female) with pronounced GHD were enrolled in a randomized, double-blind, placebo-controlled study with objectives that included effects on body composition, cardiac structure, and function and safety of replacement therapy with recombinant human GH (Saizen).

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The patients were allocated by chance, so the Human Growth Hormone group and the comparison group should start out alike.

As a double-blind Human Growth Hormone study, the assignments were hidden from both participants and investigators until the end.

Some patients received a placebo instead of Human Growth Hormone, giving a reference point.

What Was Measured

The subject headings attached to it are Body Composition, Echocardiography, Heart, Human Growth Hormone, Insulin-Like Growth Factor Binding Proteins, Insulin-Like Growth Factor I and Insulin-Like Growth Factor II.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Human Growth Hormone in 55 patients.

The publication is from 2002 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the related Exogenous HGH, sermorelin & older GHRPs (why they're passed over) library page, all human trials.